Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAXXAIR: Immunological Analysis of LAIV vs IIV Influenza Vaccines
NCT05921448Phase 1Active, not recruiting
- Sponsor
- Copenhagen Respiratory Research
- Start
- May 2025
- Primary completion
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of influenza vaccine (trivalent, inactivated) or influenza vaccine (live, attenuated, intranasal) in influenza (2 arms), sponsored by Copenhagen Respiratory Research. Primary endpoint: Mucosal immunity in nasopharynx (humoral) at Day 28. Started May 2025; status: active, not recruiting.
02
Drugs
influenza vaccine (trivalent, inactivated) or influenza vaccine (live, attenuated, intranasal)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05921448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05921448.